Navigation Links
Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
Date:1/9/2012

s (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our inte
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
3. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
4. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
7. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
8. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
9. Neuralstem Completes $5.25 Million Financing
10. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
11. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
(Date:8/31/2015)... Aug. 31, 2015 LabStyle Innovations Corp. ... Solution, today announced it recently closed a round ... be used to support the global rollout and ... mobile, cloud-based, diabetes management solution that includes novel ... blood glucose monitoring device, and for working capital ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food ... food and beverage processors, equipment manufacturers and leaders in the field of academia. ... weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry ...
Breaking Biology Technology:New Down syndrome therapy discovered 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech ... Coffey, Chief,Scientific Officer of Oncolytics, is scheduled ... 2007 entitled "Large Scale Production Process for,the ... Informa Life,Sciences, 3rd Annual Vaccine Production Conference ...
... properties of a commonly used blue dye could revolutionise ... Advanced Materials. , Scientists have demonstrated that they can ... Phthalocyanine, or MPc, with the use of magnetism. ... researchers claim that the ability to control the magnetic ...
... Calif., Nov. 28 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, is scheduled ... Conference., The presentation by Tom Chesterman, SVP and CFO ... at 1:30 p.m. local time at the,Millennium Broadway Hotel in ...
Cached Biology Technology:Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference 2Blue dye could hold the key to super processing power 2Blue dye could hold the key to super processing power 3
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... protect nerves are the likely origin of the Devil Facial ... population, an international team of scientists has discovered. ... affects only Tasmanian devils and was first reported in 1996. ... The disease is characterised by large tumours, mostly on the ...
... FL Scientists from The Scripps Research Institute have ... infectious protein devoid of DNA or RNA that can ... The study from Scripps Florida in Jupiter ... at the protein level and, through natural selection, these ...
... in the remains of long-dead plants, animals, or humans allows ... studies of this kind on ancestral members of our own ... ancient DNA from modern-day human DNA contamination. Now, research by ... Leipzig, published online on December 31st in Current Biology ...
Cached Biology News:Nervous culprit found for Tassie devil facial tumor disease 2Scripps Florida scientists show 'lifeless' prions capable of evolutionary change and adaptation 2Scripps Florida scientists show 'lifeless' prions capable of evolutionary change and adaptation 3Scripps Florida scientists show 'lifeless' prions capable of evolutionary change and adaptation 4Using modern sequencing techniques to study ancient modern humans 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: